Digital health technology can support the management of type 2 diabetes, but there are also barriers. For an overview of current applications, wearable devices and federal agency perspective, tune in to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop on September 5-6. Erich S. Huang, MD, PhD, our Head of Clinical Informatics, will be speaking on equitable digital health approaches to diabetes management in the session moderated by Dr. David Klonoff and Dr. Xujing Wang.
There is more health data than ever. But the ability of life sciences and data-generating enterprises to govern, analyze and partner on data remains a challenge, which is imperative for biomedical research and development. Data analysis platforms, like Verily Workbench, can help through the infrastructure and collaborative tools to unlock the value of multimodal health data at scale.
Living with Parkinson’s disease (PD) can be challenging. There is great potential for wearables and digital measures to provide valuable data to clinicians and people with PD. Join Verily’s Erin Rainaldi and Johnny Ho as they share an in-depth analysis and lessons learned from a study designed for PD patients using Verily’s Study Watch and a virtual motor exam. Register for the Health Research from Home webinar on September 4 at 4:00pm GMT+1.
Clinical trial staff can address technology overload and burnout by adopting an advanced clinical trial management system (CTMS) that is intuitive and easy to use. With Verily Viewpoint Site CTMS, researchers are able to enjoy CTMS-configured workflows without the burden of translating PDF protocols and other tedious tasks.
We’re celebrating our 9th birthday this month 🎉 Verily was born in 2015 at Google X, the moonshot factory to tackle health’s biggest challenges by developing tools, services and software to help customers across the healthcare ecosystem. This experimentation-centric approach led to innovations at the intersection of health and tech. Today, our focus on solutions in the areas of research, care and public health has led to new approaches that make healthcare more personalized and precise.
Clinical research sites are bogged down by the enormous, daunting task of building, running and analyzing a study as directed by the protocol. And most are executing on these essential tasks with a PDF or “paper” protocol. There’s a better way with Verily Viewpoint Site CTMS, a state-of-the-art clinical trial management system that digitizes PDF protocols so clinical trial staff doesn’t have to.
A unique feature of Verily Site CTMS, our clinical trial management system, is protocol digitization. That means taking a study protocol in PDF format and creating a structured, digital version. The use of AI can further expedite the digitization process, with the goal of enabling site research operations teams to increase the productivity and revenue of their research programs. In this study, Verily researchers demonstrated that a fine-tuned LLM (PaLM-2) model can achieve near optimal performance without requiring manual labeling, a process that is both expensive and time-consuming. Our results show that using high confidence labels generated by LLM models such as Gemini-pro can be an efficient strategy for improving LLM performance on specialized tasks such as protocol digitization. Next week at the Machine Learning for Healthcare 2024 Conference we will present this work in the research track.
A clinical trial management system (CTMS) connects, organizes and simplifies the many aspects of research site operations, freeing clinical study sites to work on other tasks. The best CTMS systems can seamlessly work together to connect data from other software and tools, such as EHRs, regulatory eBinders and patient payment systems. Learn about our solution, Viewpoint Site CTMS, designed by researchers for researchers.
Despite innovations in clinical trial design, the ways to access, acquire and use data in trials has evolved very little over time. It remains expensive, labor-intensive and limits the amount of evidence that can be collected to inform whether and how care solutions work for different patient populations. In a new paper published in JAMA, experts in clinical trials, including from Verily, explore how to overcome these limitations and propose a modern data infrastructure for clinical research. The vision addresses two critical opportunities where an updated data infrastructure is essential: 1️⃣ Bringing together data sources that are not traditionally used for clinical research, to produce better and more generalizable insights into health. 2️⃣ Maximizing the research value of data by enabling the reuse of data for multiple purposes when necessary permissions are in place. The paper describes how a modernized data infrastructure can build on existing work in this area and also emphasizes important ethical considerations.
We are proud to announce that Verily Retinal Camera (Investigational Retinal Camera) has been selected to be used in retinal image data collection for the National Eye Institute (NEI)’s eyeGENE® registry due to its image quality, ease-of-use and portability. The core mission of eyeGENE® is to facilitate research into the causes and mechanisms of rare inherited eye diseases and accelerate pathways to potential treatments. With the addition of retinal images from the Verily Retinal Camera, we hope to provide the vision research community with another tool to advance ophthalmic research. The first study to use Verily Retinal Camera will research patients with albinism and hypopigmentation, with images collected at the NOAHCon 2024 National Conference. CAUTION - Investigational device. Limited by United States law to investigational use.
